ARTICLE | Emerging Company Profile
How D3 Bio is building its biomarker-driven pipeline
Emerging Company Profile: D3 Bio’s Chen on the start-up’s internal pipeline, plans for in-licensing
December 9, 2020 12:08 AM UTC
George Chen’s D3 Bio is prioritizing its internal pipeline so it can be choosy about in-licensed assets.
The Shanghai company unveiled a $200 million series A round on Nov. 17 that was backed by a syndicate of investors including Boyu Capital, Matrix Partners China, Sequoia Capital China, Temasek, and WuXi AppTec’s Corporate Venture Fund. ...